keine Finanzberatung

DGX · Quest Diagnostics

One of America's two dominant clinical lab chains

Risiko 3/10 · LOW-MODERATE RISK · defensive lab duopolist · $237.14 ▼ 0.94%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $237.14
  • Market cap $26.2B
  • P/E (ttm) 25.2
  • Div yield 1.45%
  • 52-wk range $171.18 – $247.19
  • Index rank #364 / —

Wichtigste Risiken

  • Medicare reimbursement cuts to lab test pricing (Shareholders) — MED
  • Payer pressure squeezing already-thin lab margins (Shareholders) — MED
  • Acquisition-driven debt load in a rate-sensitive model (Bondholders) — LOW
  • Test volumes tied to healthcare utilization trends (Shareholders) — LOW

Fazit

A defensive compounder whose main enemy is the reimbursement pen, not the market cycle.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.